Free Reputation Audit
Get a confidential consultation and preliminary audit
Your information is confidential and will never be shared
Free Reputation Audit
Get a confidential consultation and preliminary audit
Your information is confidential and will never be shared
RESEARCH CENTER BY REPUTATION HOUSE, 2026
U.S. Pharma Digital Risk Research: Analysis of 17 Leading Pharmaceutical Companies
How litigation legacy, brand identity fragmentation and AI-generated content shape reputational risk across the sector. Based on a Risk Check analysis of 17 major U.S.-market pharmaceutical companies across four digital risk dimensions.
17 pharmaceutical companies analysed
4 digital risk dimensions
Q1–Q2 2026
research period
research period
Download Full Research
Enter your email and we'll send the full research within 2 minutes. Please check your spam folder if you don't see it.
Key Findings
33 / 100
average composite risk score across all 17 companies — just above the LOW/MEDIUM boundary of 31. In this sector, reputational risk is structural, not episodic.
17 of 17
companies scored MEDIUM on AI Perception — no LOW or HIGH ratings observed. AI systems consistently over-index on litigation and legacy content, regardless of how strong a company's positioning is.
16% → 59%
Consumer Sentiment Risk range, from Amgen to Eli Lilly — the widest-variance dimension in the study. It exposes the gap between strong B2B reputation and fragile B2C perception.
r = 0.56
correlation between FDA Warning Letters and composite risk (2022–2025, p ≈ 0.02). A directionally consistent signal that regulatory history feeds durable, high-authority negative content.
r = −0.42
inverse correlation between Glassdoor rating and composite risk. Companies rated 4.0+ (Amgen, Regeneron, Vertex) cluster in the lower-risk third; 3.5 and below (Catalent, Bausch Health, Organon, Moderna) in the upper third.
42 vs 24
highest- and lowest-risk composite scores — Catalent (42) against Amgen and Biogen (24 each). The gap is not safety versus crisis, but latent risk versus active exposure.
Litigation legacy
the sector's primary narrative driver. DOJ settlements, FDA warning letters and pricing lawsuits keep shaping search and AI outputs for years after the underlying matters are resolved.
Brand fragmentation
a persistent cross-channel vulnerability. Spinoffs, name collisions and subsidiary confusion — J&J/Kenvue, Merck/Merck KGaA, Bausch Health/Bausch + Lomb — cause AI and search to conflate distinct entities.
73%
of negative reviews on Yelp originate from emotionally triggered events, not systematic dissatisfaction
×2.4
higher viral spread for reviews with specific emotional language vs. neutral fact-based feedback
48h
critical window — reputation damage is 80% reversible if addressed within the first 48 hours
48h
critical window — reputation damage is 80% reversible if addressed within the first 48 hours
Methodology
17
pharmaceutical companies analysed
4
digital risk dimensions
12 months
rolling signal window (Q1–Q2 2026)
2022–2025
FDA Warning Letters cross-reference
Research Design
This study assessed the digital risk profiles of 17 pharmaceutical companies with significant U.S. market presence using Risk Check, an analytical platform developed by Reputation House. Companies were selected based on their presence in major industry rankings, public market visibility, and relevance to the U.S. healthcare landscape. Data was collected targeting the U.S. digital environment in English during Q1–Q2 2026, with signals drawn from a 12-month rolling window.
Companies Analysed
AbbVie, Amgen, Bausch Health, Biogen, Bristol-Myers Squibb, Catalent, Eli Lilly & Co, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Organon, Perrigo, Prestige Consumer Healthcare, Pfizer, Regeneron, and Vertex Pharmaceuticals.
The Four Risk Dimensions
Media & Social Risk
Exposure and vulnerability in public media and social environments, including susceptibility to narrative manipulation and coordinated negative campaigns.
SERP Risk
The degree of control a company has over its branded search engine results, and the presence of potentially harmful content in top positions.
AI Perception
The gap between a company's self-positioning and how it is interpreted by AI-generated systems such as ChatGPT, Gemini and Perplexity — whether AI represents a brand accurately, or over-indexes on controversy, litigation and legacy negative content.
Consumer Sentiment Risk
Stability of consumer trust signals across review and rating platforms including BBB, Trustpilot and Glassdoor. This dimension captures the level of sustained negative consumer-facing signals, not temporal volatility.
Scoring
Each dimension is scored from 0% to 100%, where higher scores indicate greater digital vulnerability. The Composite Risk Score (0–100) is a weighted aggregation of the four dimension scores, using fixed weights applied uniformly across all 17 companies. The weights are proprietary and not disclosed externally. Scores are classified as:
| Risk dimension | What it measures |
|---|---|
| Media & Social Risk | Exposure and vulnerability in public media and social environments, including susceptibility to narrative manipulation and coordinated negative campaigns. |
| SERP Risk | The degree of control a company has over its branded search engine results, and the presence of potentially harmful content in top positions. |
| AI Perception | The gap between a company's self-positioning and how it is interpreted by AI-generated systems such as ChatGPT, Gemini and Perplexity — whether AI represents a brand accurately, or over-indexes on controversy, litigation and legacy negative content. |
| Consumer Sentiment Risk | Stability of consumer trust signals across review and rating platforms including BBB, Trustpilot and Glassdoor. This dimension captures the level of sustained negative consumer-facing signals, not temporal volatility. |
Contents
A sector where digital reputational risk is structural, not episodic — shaped by accumulated legal histories, brand fragmentation and the growing influence of AI-generated content on brand perception.
How Risk Check scores 17 companies across four dimensions — Media & Social, SERP, AI Perception and Consumer Sentiment — into a single composite risk score on a 0–100 scale.
Every company scored MEDIUM on AI Perception. AI systems draw on high-authority sources — Wikipedia, government databases, litigation records — and foreground regulatory and legacy content over current positioning.
A modest sector average is misleading. Most companies are not in crisis, but carry latent vulnerabilities that can escalate quickly under a new regulatory action, recall or adverse media cycle.
DOJ settlements, FDA warning letters and pricing lawsuits create a permanent record in high-authority environments that shapes search and AI outputs for years after the matters are resolved.
Spinoffs, name collisions and subsidiary confusion cause AI and search to conflate distinct entities — a vulnerability traditional reputation management cannot address on its own.
The widest-variance dimension, from 16% to 59%. It captures the gap between strong institutional B2B reputation and more fragile consumer-facing perception on review and complaint platforms.
All 17 companies ranked by composite risk score, with the four dimension scores for each — from Catalent (42) at the top to Amgen and Biogen (24) at the base.
A detailed risk profile for each company: vulnerability-zone scores, primary risk factors and the key finding from the diagnostic.
Four priority actions for pharma communications leaders — audit your AI footprint, address identity fragmentation, treat legacy litigation as ongoing, and monitor Glassdoor as a leading indicator.
Data Preview
Risk Rankings: 17 companies by composite score
Consumer Sentiment Risk across the sector
Full charts and all 17 company profiles are available in the downloaded PDF.
“
AI systems don't describe pharma companies the way those companies describe themselves. Across all 17 in this study, AI-generated summaries foregrounded litigation, FDA actions and legacy controversies — including matters already resolved — over current positioning. The gap between institutional reputation and AI-mediated perception is now a category of risk in its own right.
KEY FINDINGS AND STRATEGIC FRAMEWORKS
Get the full research
Enter your email and we'll send the full research instantly. A sector-wide diagnostic of 17 U.S. pharmaceutical companies across four digital risk dimensions.
We don't share your data. No sales calls, no spam.
Who should read this pharma digital risk research
Pharma CMOs & Corporate Communications
If you own brand reputation across search and AI, this research maps where the sector is exposed. See how AI systems foreground litigation and legacy content over current positioning — a gap that traditional PR and SERP work don't close — and where your company sits across four risk dimensions.
PR & Regulatory Communications Leads
For teams managing resolved and active regulatory matters: the data shows why FDA warning letters, DOJ settlements and pricing lawsuits keep shaping AI and search for years after closure, and why legacy litigation has to be treated as an ongoing communications challenge, not a closed chapter.
Investor Relations, Risk & Compliance
For public pharma companies, digital reputation is a measurable exposure. This research quantifies how litigation legacy, brand fragmentation and consumer-sentiment signals feed AI-mediated perception — and introduces Glassdoor's −0.42 correlation as a 3–6-month early-warning indicator for risk teams.
Frequently Asked Question
The average composite risk score across the 17 companies is 33 out of 100 — just above the LOW/MEDIUM boundary of 31. Eleven of the 17 companies fall in the MEDIUM band; six fall in LOW. In this sector, risk is structural rather than tied to any single active crisis.
Each company is scored across four dimensions of digital exposure: Media & Social Risk, SERP Risk, AI Perception, and Consumer Sentiment Risk. Each dimension is scored 0–100%, and the four are aggregated into a single composite risk score on a 0–100 scale.
Catalent has the highest composite score at 42; Amgen and Biogen are lowest at 24 each. The gap reflects active exposure versus latent risk, not a difference between crisis and safety — both sit inside the same MEDIUM-leaning sector profile.
No. A modest score signals latent, not absent, risk. Most companies analysed are not in crisis, but carry structural vulnerabilities that can escalate quickly under a new regulatory action, product recall, pricing controversy or adverse media cycle.
All 17 companies scored MEDIUM on AI Perception, with no LOW or HIGH ratings. AI systems draw on high-authority sources — Wikipedia, government databases, litigation records — that foreground regulatory and legacy content. This is reported as an early-stage observational signal, pending metric maturation.
AI-generated summaries tend to over-index on litigation, FDA actions and historical controversies over current corporate positioning — including matters already resolved. A patient, investor or journalist using AI to research a company may receive a description weighted toward regulatory scrutiny.
Not on their own. The gap between corporate positioning and AI-mediated description isn't addressed by SERP optimisation or press relations. It requires AI-facing work: authoritative brand disambiguation content, structured data and consistent identity cues across indexed sources.
Resolved legal matters do not disappear from digital environments. DOJ settlements, FDA warning letters, pricing lawsuits and class actions create a permanent record in high-authority sources that shapes search results and AI outputs for years after the underlying issue is closed.
Cross-referencing composite scores with the FDA Warning Letters database (2022–2025) yields a Spearman correlation of r = 0.56 (p ≈ 0.02). Given the small sample, this is a directionally consistent, exploratory association rather than a confirmation — a signal that regulatory history feeds high-authority negative content.
The pattern appears sector-wide, including Gilead Sciences (DOJ settlement), Regeneron (Eylea pricing litigation), Moderna (UK regulatory reprimand and patent disputes), Eli Lilly (FDA warning letter and pricing lawsuits) and Pfizer (regulatory and compliance legacy). The legal event may be concluded; the digital signal persists.
Consumer Sentiment Risk shows the widest variance, ranging from 16% (Amgen) to 59% (Eli Lilly). It captures the gap between a company's strong B2B institutional reputation and its more fragile B2C, consumer-facing reputation on review and complaint platforms.
Glassdoor ratings correlate inversely with composite risk at r = −0.42. Companies rated 4.0+ cluster in the lower-risk third; those at 3.5 and below concentrate in the upper third. Employee sentiment tends to precede consumer-facing reputation shifts by three to six months.
Brand identity fragmentation is the confusion created by spinoffs, name collisions and subsidiary structures — J&J/Kenvue, Merck/Merck KGaA, Bausch Health/Bausch + Lomb, Perrigo/Prestige. It causes AI and search systems to conflate distinct entities, a cross-channel vulnerability traditional reputation management can't fix alone.
Get the full research — free PDF
26 pages · 17 company profiles · charts · recommendations
Order Custom Research
Get a tailored research proposal for your market or company